Preoperative prognostic nutritional index and systemic immune inflammation index for predicting the efficacy and survival time of patients with osteosarcoma undergoing neoadjuvant chemotherapy combined with surgery.

IF 3.6 3区医学 Q2 ONCOLOGY American journal of cancer research Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI:10.62347/MHXS8480

Jin Jiang, Tingxiao Zhao, Longtao Yao, Tao Zhang, Lichen Ji, Wei Zhang, Yanlei Li, Jinlong Tian, Xiaoyan Ding, Yongqin Lin, Liang Han

{"title":"Preoperative prognostic nutritional index and systemic immune inflammation index for predicting the efficacy and survival time of patients with osteosarcoma undergoing neoadjuvant chemotherapy combined with surgery.","authors":"Jin Jiang, Tingxiao Zhao, Longtao Yao, Tao Zhang, Lichen Ji, Wei Zhang, Yanlei Li, Jinlong Tian, Xiaoyan Ding, Yongqin Lin, Liang Han","doi":"10.62347/MHXS8480","DOIUrl":null,"url":null,"abstract":"Objective: To explore the value of preoperative prognostic nutritional index (PNI) and systemic immune inflammation index (SII) for predicting the efficacy and prognosis of patients with osteosarcoma undergoing neoadjuvant chemotherapy (NACT) combined with surgery.Methods: A retrospective study was conducted on patients with osteosarcoma undergoing NACT combined with surgery in Sun Yat-sen University Cancer Center from January 2017 to May 2019. The patients were grouped into a remission group (pCR group, 85 patients) and a non-remission group (non-pCR, 79 patients), according to the treatment efficacy. The pathological data as well as clinical data were collected from patients, which were subsequently employed for statistical analysis to determine the factors affecting the efficacy of the treatment. The diagnostic value of PNI and SII for predicting the efficacy were assessed through following up the patients for 5 years to observe their overall survival rate. COX regression analysis was leveraged to identify risk factors affecting the survival time. The impact of different PNI and SII levels on the survival time was observed.Results: Multivariate regression analysis showed that factors including Enneking stage, PNI level and SII level were in association with poor efficacy after NATC combined with surgery. The mortality within 5 years was higher and the 5-year overall survival rate was lower in the non-pCR group than those in the pCR group (both P < 0.05). The COX regression analysis indicated that PNI and SII levels were risk factors for poor prognosis in patients with osteosarcoma following NACT combined with surgery. Further analysis showed that patients with low PNI and high SII levels had a lower 5-year survival rate (P < 0.05).Conclusion: Enneking stage, PNI, and SII levels were risk factors for poor efficacy in patients with osteosarcoma after NACT combined with surgery. Patients whose PNI level was low and SII level was high presented poor prognosis following the treatment.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4946-4955"},"PeriodicalIF":3.6000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560818/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/MHXS8480","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore the value of preoperative prognostic nutritional index (PNI) and systemic immune inflammation index (SII) for predicting the efficacy and prognosis of patients with osteosarcoma undergoing neoadjuvant chemotherapy (NACT) combined with surgery.

Methods: A retrospective study was conducted on patients with osteosarcoma undergoing NACT combined with surgery in Sun Yat-sen University Cancer Center from January 2017 to May 2019. The patients were grouped into a remission group (pCR group, 85 patients) and a non-remission group (non-pCR, 79 patients), according to the treatment efficacy. The pathological data as well as clinical data were collected from patients, which were subsequently employed for statistical analysis to determine the factors affecting the efficacy of the treatment. The diagnostic value of PNI and SII for predicting the efficacy were assessed through following up the patients for 5 years to observe their overall survival rate. COX regression analysis was leveraged to identify risk factors affecting the survival time. The impact of different PNI and SII levels on the survival time was observed.

Results: Multivariate regression analysis showed that factors including Enneking stage, PNI level and SII level were in association with poor efficacy after NATC combined with surgery. The mortality within 5 years was higher and the 5-year overall survival rate was lower in the non-pCR group than those in the pCR group (both P < 0.05). The COX regression analysis indicated that PNI and SII levels were risk factors for poor prognosis in patients with osteosarcoma following NACT combined with surgery. Further analysis showed that patients with low PNI and high SII levels had a lower 5-year survival rate (P < 0.05).

Conclusion: Enneking stage, PNI, and SII levels were risk factors for poor efficacy in patients with osteosarcoma after NACT combined with surgery. Patients whose PNI level was low and SII level was high presented poor prognosis following the treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

预测接受新辅助化疗联合手术的骨肉瘤患者疗效和生存时间的术前预后营养指数和全身免疫炎症指数。

目的探讨术前预后营养指数（PNI）和全身免疫炎症指数（SII）对接受新辅助化疗（NACT）联合手术治疗的骨肉瘤患者疗效和预后的预测价值：2017年1月至2019年5月，中山大学肿瘤防治中心对接受新辅助化疗（NACT）联合手术治疗的骨肉瘤患者进行了回顾性研究。根据疗效将患者分为缓解组（pCR组，85例）和非缓解组（non-CR组，79例）。研究人员收集了患者的病理数据和临床数据，并对其进行统计分析，以确定影响疗效的因素。通过对患者进行为期 5 年的随访，观察他们的总生存率，评估 PNI 和 SII 在预测疗效方面的诊断价值。利用 COX 回归分析确定影响存活时间的风险因素。观察了不同 PNI 和 SII 水平对生存时间的影响：多变量回归分析显示，恩内景分期、PNI水平和SII水平等因素与NATC联合手术后疗效不佳有关。与 pCR 组相比，非 pCR 组 5 年内死亡率更高，5 年总生存率更低（P 均<0.05）。COX回归分析表明，PNI和SII水平是NACT联合手术后骨肉瘤患者预后不良的危险因素。进一步分析表明，PNI和SII水平较低的患者5年生存率较低（P<0.05）：结论：Enneking分期、PNI和SII水平是骨肉瘤患者接受NACT联合手术后疗效不佳的风险因素。PNI水平低和SII水平高的患者治疗后预后较差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.